CARDIOVASCULAR
Outcomes Research in Ischemic Heart Disease
Clinical Trials in Acute Ischemic Syndrome
Mechanisms of Sudden Death, Basic EP Lab.
MAJOR RESEARCH INTERESTS
Outcomes Research in Ischemic Heart Disease
Clinical Trials in Acute Ischemic Syndrome
Mechanisms of Sudden Death, Basic EP Lab
CO-INVESTIGATOR – CARDIOVASCULAR RESEARCH
Effect of calcium antagonist on extracellular ionic changes in schemic porcine myocardium. American Heart Association 1989-1990.
Activase Registry: A Genentech-sponsored registry of all myocardinal infarction patients.
Genentech Effects of ATP-dependent K+ channel blockers and activators on ionic and electrical changes in the ischemic porcine myocardium. American Heart Association 1990-1991.
Thrombosis in Myocardial Infarction Ill-B (TIMI Ill-B): Examines the role of t-PA and aggressive versus conservative management in unstable angina and non-Q wave myocardial infarction. NIH funded.
Thrombolysis in Myocardial Infarction Ill-B Registry: A Natural History Study Looking at Outcome of minorities and Women with Unstable Angina or non-Q wave Myocardial Infarction.
Thrombolysis in Myocardial Infarction VI ((TIMI VI) I VI): Comparison of Recombinant Hirudin and Heparin when Given in Conjunction with Streptokinase to Patients with Acute Transmural Myocardial Infarction. NIH 1993-1994.
MK 852: A safety study on use of MK 852, a platelet inhibitor, in patients with unstable angina. A comparison of MK 852 to heparin. Merck Pharmaceutical 1993
MK 3 83: Phase III Trail on platelet inhibition in patients with unstable angina. Merck Pharmaceutical, 1994-1996.
Designed and evaluated a critical pathway for the management of complicated and uncomplicated MI. Hospital 1992-1996.
Essence Trail: Phase II Trail use of low molecular weight Heparin in unstable angina. CIBA Pharmaceutical 1995-1996.
Use CQI techniques to improve the quality of service on the Cardiology consult service. No funding. Hospital 1991-1996
TIMI 9A/9B – Phase III Trail use of Hirudin as adjunctive therapy in patients receiving Thromobolytic Agents for Acute Myocardial Infarction. CIBA
RELY TRIAL – Phase III Trail use of Pradaxa as an anti-coagulant to prevent strokes in patients with Atrial Fibrillation.
